Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;270(3):1754-1758.
doi: 10.1007/s00415-022-11480-6. Epub 2022 Nov 12.

Neurofilament light chain: a promising diagnostic biomarker for functional motor disorders

Alessandro Dinoto #  1 , Enrico Marcuzzo #  1 , Vanessa Chiodega #  1 , Francesco Dall'Ora #  1 , Sara Mariotto #  2 , Michele Tinazzi #  3
Affiliations

Neurofilament light chain: a promising diagnostic biomarker for functional motor disorders

Alessandro Dinoto et al. J Neurol. 2023 Mar.

Abstract

Objective: Functional motor disorders (FMDs) are disabling neurological conditions characterized by abnormal movements which are inconsistent and incongruent with recognized neurological diseases. Aim of this study is to investigate whether FMDs are related to structural axonal damage.

Methods: Consecutive patients with a definite diagnosis of FMD with no other neurological/psychiatric comorbidities (pure FMDs) and age-matched healthy controls (HCs) were recruited in a tertiary center and demographic/clinical data were collected. Serum neurofilament light chain (NfL) assessment was performed with ultrasensitive paramagnetic bead-based enzyme-linked immunosorbent assay.

Results: 34 patients with FMDs and 34 HCs were included. NfL levels were similar (p = 0.135) in FMDs (median 8.3 pg/mL, range 2-33.7) and HCs (median 6.1 pg/mL, range 2.7-15.6). The area under curve (0.606, 95% CI 0.468-0.743) confirmed that NfL concentration was not different in the two groups. NfL values were similar in patients with paroxysmal vs persistent disease course (p = 0.301), and isolated vs combined symptoms (p = 0.537). NfL levels were associated with age (p < 0.0001), but not with disease duration (p = 0.425), number of CNS acting drugs (p = 0.850), or clinical features (p = 0.983).

Discussion: Our preliminary data show that NfL levels are similar in patients with FMDs and HCs, indicating the lack of neuroaxonal damage. These results have relevant pathogenic and clinical implications and suggest that serum NfL may be a promising diagnostic biomarker, potentially useful to differentiate functional vs structural neurological disorders.

Keywords: Biomarkers; Functional motor disorders; Movement disorders; Neurofilament light chain.

PubMed Disclaimer

References

    1. Tinazzi M, Fiorio M, Berardelli A et al (2022) Opinion, knowledge, and clinical experience with functional neurological disorders among Italian neurologists: results from an online survey. J Neurol 269:2549–2559. https://doi.org/10.1007/s00415-021-10840-y - DOI - PubMed
    1. Espay AJ, Aybek S, Carson A et al (2018) Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol 75:1132–1141. https://doi.org/10.1001/jamaneurol.2018.1264 - DOI - PubMed - PMC
    1. Demartini B, Nisticò V, Edwards MJ et al (2021) The pathophysiology of functional movement disorders. Neurosci Biobehav Rev 120:387–400. https://doi.org/10.1016/j.neubiorev.2020.10.019 - DOI - PubMed
    1. Sasikumar S, Strafella AP (2021) The neuroimaging evidence of brain abnormalities in functional movement disorders. Brain. https://doi.org/10.1093/brain/awab131/6179314 - DOI - PubMed - PMC
    1. Mariotto S, Gajofatto A, Zuliani L et al (2019) Serum and CSF neurofilament light chain levels in antibody—mediated encephalitis. J Neurol 266:1643–1648. https://doi.org/10.1007/s00415-019-09306-z - DOI - PubMed

LinkOut - more resources